This is an open label phase II trial to examine efficacy and safety of a novel combination of
pembrolizumab plus induction GM-CSF in patients with advanced biliary cancers treated at
University of California, San Francisco (UCSF).
This phase II study will examine the efficacy and safety of the novel combination of
pembrolizumab plus induction GM-CSF in advanced biliary cancer patients with the hypotheses
that the combination may increase proportion of patients with overall response compared to
contemporary historical controls, with acceptable safety.
Phase:
Phase 2
Details
Lead Sponsor:
Robin Kate Kelley
Collaborators:
American Society of Clinical Oncology Merck Sharp & Dohme Corp.